Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director · CEO, President | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 273,362 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 2,424 · Balance 273,362 F1: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2018 Filed May 11, 2018 23:29 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-006677 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: On February 2, 2017 the reporting person was granted an option to purchase 450,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On May 9, 2018, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001140 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-006152 · edgar.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2026-01-26 F2 · derivative.exercise_date: On January 26, 2016 the reporting person was granted an option to purchase 400,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001179110-17-006152 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-02-27 F1 · derivative.exercise_date: On February 27, 2014 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. As previously reported on April 4, 2016, the Compensation Committee determined that the performance condition had been achieved with respect to 75,000 shares of common stock. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved with respect to the remaining 75,000 shares of common stock, resulting in full vesting of the option. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:22 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001814 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.